Buprenorfina en el manejo de dolor por cáncer

María Catalina  Soto Niño

Authors

María Catalina Soto Niño Instituto Nacional de Cancerología

Keywords:

Oncological pain, transdermal buprenorphine, opiods

Abstract Authors References How to Cite

Abstract

Opiods are the current pharmalogical remedies of choice for the control of moderate to severe pain. Subsequently, it is important to rely on a number of prescriptions and applications for these drugs, particularly in the case of oncological patients. Low molecular weight, high potency and liposolubility of buprenorphine combine with its favorable tolerance and low abuse probability. Clinical evidence reveals that the use of transdermal buprenorphine in the treatment of moderate to severe pain in oncological patients is effective and safe. However, buprenorphine has not been widely studied among certain populations, as have other opiods, thus making further research necessary in order to define its role under specific clinical circumstances.

Author Biography

María Catalina Soto Niño, Instituto Nacional de Cancerología

Instituto Nacional de Cancerología. Bogotá, Colombia.

References

Hanks GW. Cancer pain and the importance of its control. Anticancer Drugs. 1995;6 Suppl 3:14-7.

https://doi.org/10.1097/00001813-199504003-00003

World Health Organization. Cancer Pain relief: with a guide to opioid availability. 2nd ed. Geneva: World Health Organization; 1996.

Zech D, Grond S, Lynch J, Hertel D, Lehmann K. Validation of World Health Organization Guidelines for cancer pain relief: A 10-year prospective study. Pain. 1995;63(1):65-76.

https://doi.org/10.1016/0304-3959(95)00017-M

Davis MP. Buprenorphine in cancer pain. Support Care Cancer. 2005;13(11):878-87.

https://doi.org/10.1007/s00520-005-0849-9

Evans HC, Easthope SE. Transdermal buprenorphine. Drugs. 2003;63(19):1999-2010.

https://doi.org/10.2165/00003495-200363190-00003

Sittl R. Transdermal buprenorphine in cancer pain and palliative care. Palliat Med. 2006;20 Suppl 1:s25-30.

Skaer TL. Transdermal opioids for cancer pain. Health Qual Life Outcomes. 2006;4:24.

https://doi.org/10.1186/1477-7525-4-24

Zaki PA, Keith DE, Brine GA, Carroll FI, Evans CJ. Ligandinduced changes in surface mu-opioid receptor number: relationship to G protein activation? J Pharmacol Expert Ther. 2000; 292(3):1127-34.

Budd K. Immunosuppressive effects induced by opioid analgesics. Int Monit Reg Anaesth and Pain Management. 2000;14:3-7.

Mercadante S, Ferrera P, Villari P. Is there a ceiling effect of transdermal buprenorphine? Preliminary data in cancer patients. Support Care Cancer. 2007;15(4):441-4.

https://doi.org/10.1007/s00520-006-0169-8

Poulsen Nautrup B, Nuijten MJC. Retrospective analysis of drug utilization patterns in cancer and non-cancer patients treated with transdermal buprenorphine and transdermal fentanyl. Value Health. 2005;8:411-2.

https://doi.org/10.1016/S1098-3015(10)63122-1

Sittl R, Likar R, Nautrup B. Equipotent does of transdermal fentanyl and transdermal buprenorphine in patients with cancer and noncancer pain: results of a retrospective cohort study. Clin. Ther. 2005;27(2):225-37.

https://doi.org/10.1016/j.clinthera.2005.02.012

Ficha técnica de Buprenorfina transdermica Transtec® Grunenthal. 2002.

Bullinham R, McQuay HJ, Porter E, Allen MC, Moore R. Sublingual buprenorphine used postoperatively: ten hour plasma drug concentration analysis. Br J Clin Pharmacol 1982;13(5):665-73.

https://doi.org/10.1111/j.1365-2125.1982.tb01434.x

Sittl R. Buprenorphine transdermal patch: clinical expert report. Germany: Grünenthal GmbH. 2000.

Sittl R, Griessinger N, Likar R. Analgesic efficacy and tolerability of transdermal buprenorphine in patients with inadequately controlled chronic pain related to cancer and other disorders: a multicenter, randomized, double-blind, placebo-controlled trial. Clin Ther. 2003;25(1):150-68.

https://doi.org/10.1016/S0149-2918(03)90019-1

Sacerdote P, Manfredi B, Mantegazza P, Panerai AE. Antinociceptive and immunosuppressive effects of opiate drugs: a structure-related activity study. Br J Pharmacol. 1997;121(4):834-40.

https://doi.org/10.1038/sj.bjp.0701138

Van Loveren, Gianotten N, Hendriksen CF, Schuurman HJ, Van der Laan JW. Assessment of immunotoxicity of buprenorphine. Lab Anim. 1994;28(4):355-63.

https://doi.org/10.1258/002367794780745119

Johnson RE, Fudala PJ, Payne R. Buprenorphine: considerations for pain management. J Pain Symptom Manage. 2005;29(3):297-326.

https://doi.org/10.1016/j.jpainsymman.2004.07.005

Schriek P. Treatment of cancer-related pain with transdermal buprenorphine: a report of three cases. Support Care Cancer. 2004;12(12):882-4.

https://doi.org/10.1007/s00520-004-0695-1

Muriel C y Grupo de Estudio de Opioides de la Sociedad Española de Dolor. Valoración del parche transdérmico de buprenorfina en pacientes con dolor oncológico. Rev Soc Esp Dolor. 2004;11 Supl V:41-8.

Griessinger N, Sittl R, Likar R. Transdermal buprenorphine in clinical practice - post-marketing surveillance study of 13, 179 patients. Cur Med Res Opin. 2005;21(8):1147-56.

https://doi.org/10.1185/030079905X53315

Sorge J, Sittl R. Transdermal buprenorphine in the treatment of chronic pain: results of a phase III, multicenter, randomized, double blind, placebo controlled study. Clin Ther. 2004; 26(11):1808-20.

https://doi.org/10.1016/j.clinthera.2004.11.008

Böhme K, Likar R. Efficacy and tolerability of a new opioid analgesic formulation, buprenorphine transdermal therapeutic system (TDS), in the treatment of patients with chronic pain. A randomised, double blind, placebocontrolled study. The Pain Clinic. 2003; 15(2):193-202.

https://doi.org/10.1163/156856903321579334

Likar R, Kayser H, Sittl R. Long-term management of chronic pain with transdermal buprenorphine: a multicenter, open-label, follow-up study in patients from three shortterm clinical trials. Clin Ther. 2006;28(6):943-52.

https://doi.org/10.1016/j.clinthera.2006.06.012

Daha A, Yassen A, Bijl H, Romberg R, Sarton E, Tepema L, et al. Comparison of the respiratory effects of intravenous buprenorphine and fentanyl in humans and rats. Br J Anaesth. 2005;94(6):825-34.

https://doi.org/10.1093/bja/aei145

Kögel B, Christoph T, Straburger W, Friederichs E. Interaction of opioid receptor agonist and antagonist with the analgesic effect of buprenorphine in mice. Eur J Pain. 2005; 9(5):599-611.

https://doi.org/10.1016/j.ejpain.2005.02.002

Jasinki J, Pevnik J, Grifith J. Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction. Arch Gen Psychiatry. 1978;35(4):501-16.

https://doi.org/10.1001/archpsyc.1978.01770280111012

Mercadante S, Arcuri E. Opioids and renal function. J Pain. 2004;5(1):2-19.

https://doi.org/10.1016/j.jpain.2003.09.007

Kaiko R, Wallenstein S, Rogers A, Grabinski P, Houde R. Narcotics in elderly. Med Clin North Am. 1982;66(5):1071-89.

https://doi.org/10.1016/S0025-7125(16)31383-9